Free Trial
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel
OTCMKTS:INTI

Inhibitor Therapeutics Q4 2024 Earnings Report

Inhibitor Therapeutics logo
$0.08 -0.01 (-7.78%)
As of 06/5/2026 11:52 AM Eastern
ProfileEarnings History

Inhibitor Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Inhibitor Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inhibitor Therapeutics Announcement Details

Quarter
Q4 2024
Date
3/28/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Inhibitor Therapeutics Earnings Headlines

Inhibitor Therapeutics Sues Investor Over Failed Financing Deal
April 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inhibitor-therapeutics-sues-investor-over-failed-financing-deal?utm_source=marketbeat.com&utm_medium=referral
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
March 31, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/inhibitor-therapeutics-provides-clinical-formulation-and-ip-update-on-itraconazole-program-for-gorlin-syndrome-1035982429
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
June 6 at 1:00 AM  |  Porter & Company (Ad)
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265972/0/en/inhibitor-therapeutics-provides-clinical-formulation-and-ip-update-on-itraconazole-program-for-gorlin-syndrome.html
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
January 24, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/01/23/10321332.htm
Prelude Therapeutics to Pause Development of Cancer Drug
November 4, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/prelude-therapeutics-to-pause-development-of-cancer-drug-7cbd9c8b
See More Inhibitor Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibitor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibitor Therapeutics and other key companies, straight to your email.

About Inhibitor Therapeutics

Inhibitor Therapeutics (OTCMKTS:INTI), a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

View Inhibitor Therapeutics Profile
Earnings Tools